Ongoing important trials
Immuncell-LC + gemcitabine — resected PDAC adjuvant (phase III)
An Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Immuncell-LC Therapy Combined With Gemcitabine Versus Adjuvant Gemcitabine Alone After Curative Resection in Patients With Pancreatic Cancer
- Phase
- Phase III
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT04969731
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? After pancreas cancer surgery, a trial tests immune-cell therapy plus chemotherapy.
Why promising? Tests adjuvant cellular immunotherapy in resected PDAC in randomized phase III.
What is not proven? No results yet; mFOLFIRINOX remains the reference context for fit patients in the West.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; recruiting (KR). No results yet.
Cancer / population: Pancreas — Rezeke PDAC
Intervention: Adjuvan Immuncell-LC + gemsitabin
Primary endpoint: Protokol tanımlı DFS/OS
Limitations: Coğrafi erişim; gemsitabin kontrol kolu seçimi tartışmalı olabilir.